Table 2 Incidence rates of primary composite outcome, acute myocardial infraction, stroke, and heart failure among new users of DPP-4 inhibitors, sulfonylureas, and metformin.
Outcome, n | DPP-4 inhibitors | Sulfonylureas | Metformin |
|---|---|---|---|
Primary composite outcome1 | 510 | 1301 | 4781 |
Total person years | 5578 | 10,696 | 57,134 |
Rate per 1000 person years | 91.25 | 121.63 | 79.46 |
Median [IQR] observation time, days | 160 [92, 286] | 144 [75, 288] | 163 [93, 300] |
Rate difference (95% CI)2 | – | − 30.20 [− 40.47, − 19.89] | 7.75 [− 0.45, 15.96] |
Acute myocardial infarction | 54 | 132 | 450 |
Total person years | 5898 | 11,487 | 60,159 |
Rate per 1000 person years | 9.16 | 11.49 | 7.06 |
Median [IQR] observation time, days | 167 [98, 297] | 161 [90, 308] | 172 [100, 314] |
Rate difference (95% CI)2 | – | − 2.34 [− 5.45, 0.80] | 1.68 [− 0.91, 4.22] |
Stroke | 141 | 268 | 1202 |
Total person years | 5839 | 11,380 | 59,592 |
Rate per 1000 person years | 24.15 | 23.55 | 20.17 |
Median [IQR] observation time, days | 167 [97, 295] | 159 [90, 305] | 171 [99, 311] |
Rate difference (95% CI)2 | – | 0.60 [− 4.31, 5.47] | 3.98 [− 0.19, 8.14] |
Heart failure | 24 | 87 | 240 |
Total person years | 5912 | 11,512 | 60,277 |
Rate per 1000 person years | 4.06 | 7.56 | 3.98 |
Median [IQR] observation time, days | 168 [98, 298] | 161[90,308] | 172 [100, 314] |
Rate difference (95% CI)2 | – | − 3.50 [− 5.78, − 1.21] | 0.08 [− 1.64, 1.82] |
